Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT II: Molecular Profiling and Targeted Agents in Metastatic Cancer
NCT02152254Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2014
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic cancer (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival. Started May 2014; status: active, not recruiting.
02
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT02152254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152254.